Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice

18 Aug 2017

Abstract excerpt

Abstract Purpose: We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse. Experimental Design: We studied responses to various mono- and bifunctional alkylating agents in a genetically engineered mouse model for BRCA1/p53-mutant breast cancer. Because of the large intragenic deletion of the Brca1 gene, no restoration of BRCA1 function...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28821557
DOI: 10.1158/1078-0432.ccr-17-1279

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in MicePMID 28821557Read ↗

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.Semantic proximity Read ↗

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivoSemantic proximity Read ↗

<i>CDKN1B</i> (p27 <sup>kip1</sup> ) enhances drug tolerant persister CTCs by restricting polyploidy following mitotic inhibitorsSemantic proximity Read ↗

FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.Semantic proximity Read ↗

Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-DamageSemantic proximity Read ↗

Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation.Semantic proximity Read ↗

The EGFR inhibitor osimertinib promotes a dynamic Drug Tolerant Persister state marked by replication defects and genome instabilitySemantic proximity Read ↗

Basal p21 controls population heterogeneity in cycling and quiescent cell cycle statesSemantic proximity Read ↗

FANCD1/BRCA2 Plays Predominant Role in the Repair of DNA Damage Induced by ACNU or TMZSemantic proximity Read ↗

Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriersSemantic proximity Read ↗

Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.Semantic proximity Read ↗

Rhodacyanine Derivative Selectively Targets Cancer Cells and Overcomes Tamoxifen ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.